LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired GoodRx Holdings, Inc. (“GoodRx” or the “Company”) (NASDAQ: GDRX) Class A common stock between September 23, 2020 and November 16, 2020 inclusive (the “Class Period”). GoodRx investors have until February 16, 2021 to file a lead plaintiff motion.
If you suffered a loss on your GoodRx investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/goodrx-holdings-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at email@example.com to learn more about your rights.
In September 2020, GoodRx completed its initial public offering (“IPO”), selling over 39.8 million common shares for $33 per share. GoodRx provides consumers with free information and tools to compare prices for prescription drugs. The Company primarily earns revenue from its prescription transaction fees.
On November 17, 2020, Amazon.com, Inc. (“Amazon”) announced two new pharmacy offerings, a Prime Rx plan and a discount card program, that would directly compete with GoodRx’s platform.
On this news, the Company’s stock price fell $10.51, or 23%, to close at $36.21 per share on November 17, 2020, thereby injuring investors.
The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Amazon had been in the process of developing and would soon introduce its own online and mobile prescription medication ordering and fulfillment service; and (2) that Amazon’s services would directly replicate and compete with the GoodRx business model.
If you purchased or otherwise acquired GoodRx Class A common stock during the Class Period, you may move the Court no later than February 16, 2021 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to firstname.lastname@example.org, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.